Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.
about
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.Pharmacotherapy of Anal Cancer.Clinical utility of circulating cell-free DNA in advanced colorectal cancer.Telomere Dynamics in Immune Senescence and Exhaustion Triggered by Chronic Viral Infection.Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients.Radiation generates an abscopal response and complete resolution of metastatic squamous cell carcinoma of the anal canal: a case report.Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.Immune Checkpoint Inhibitors in Melanoma and HIV Infection.Trial watch: Immune checkpoint blockers for cancer therapy.Skin microbiota-host interactions.Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab.Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma.Cancer vaccine: learning lessons from immune checkpoint inhibitors.Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients.Treatment of squamous cell carcinoma of the anal canal (SCCA): a new era?Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers.Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in CancerPrognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New EvidencesRecent advances in the management of anal cancerCheckpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations
P2860
Q38642853-F99EC017-91F6-49F4-A9CA-6A39885FE6ADQ38647761-6742E60D-D525-4D32-9F62-063E0D99767EQ41545171-F459D6FE-70D2-4039-9EC5-7594EB3E9EC1Q41923721-DDB623F1-3A95-4C08-8EA9-A3D07EA9EE5FQ47094138-B645DFE5-0A3D-45C4-AAF8-AF436E50C354Q47098450-847D18D1-66A3-4762-AE59-24E1E4B76C5FQ47101155-E61A92D2-78C9-4B46-A187-415E04C05367Q47138765-B7C8A251-8598-48C4-8ECB-DC009F3310D7Q47393365-0CF26126-FEFC-45DB-940E-B3C1251F7368Q47549354-4CEB0746-DACF-4331-8F87-1177E11AE572Q47713714-F2BF7EC3-2190-471F-AE48-881EEC5DF168Q47936526-E6D30DC3-6B97-4AD6-B1C9-52B020C537B0Q49228103-3C241A17-B9AC-4A57-B4B5-78B559BAB608Q49260236-C44E3D90-9D0C-4750-828B-CE3F1BB0EA00Q49821280-12191923-953A-4395-B058-3077B5C4BEADQ49842285-3641F295-3A2C-4C5F-BD92-53616F5A300EQ52683991-985DF8F8-6855-45C1-9610-9EFABA22203CQ54116465-7D852F20-A58A-4F09-A739-FA504205B814Q55497366-BD85CB31-662B-4A6E-9606-785A5D80F041Q55652233-D1287B9B-DBAC-4ADA-BD60-BC1ED1709D40Q56891212-41F78D6B-A0DE-42C0-93D9-C05610915F79Q57191808-A26249B0-70EB-49CB-A7DC-0862DE29C6AEQ57821008-11729451-B5EB-40AF-8E1A-A9C13C6BC992Q59135661-A5667BA3-4EDE-4BD4-AE19-047650DA024F
P2860
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Nivolumab for previously treat ...... re, single-arm, phase 2 study.
@en
type
label
Nivolumab for previously treat ...... re, single-arm, phase 2 study.
@en
prefLabel
Nivolumab for previously treat ...... re, single-arm, phase 2 study.
@en
P2093
P2860
P1433
P1476
Nivolumab for previously treat ...... re, single-arm, phase 2 study.
@en
P2093
Aki Ohinata
Amir Mehdizadeh
Armeen Mahvash
Blase Polite
Chimela Ohaji
Dustin Deming
Emily Chan
Gail Bland
Halla Nimeiri
P2860
P304
P356
10.1016/S1470-2045(17)30104-3
P577
2017-02-17T00:00:00Z